Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sagimet Biosciences, Inc. Class A (SGMT) just unveiled an announcement.
Sagimet Biosciences Inc. has appointed Thierry Chauche as their new Chief Financial Officer, effective May 6, 2024. Chauche brings over two decades of financial leadership in the healthcare sector, with previous roles at Provention Bio, Alexion Pharmaceuticals, and Novartis AG. His comprehensive employment package includes a $480,000 base salary, potential for a 40% bonus, and standard employee benefits, along with severance benefits under certain conditions. Additionally, Chauche has been granted significant equity in the company, which will vest over four years, to incentivize his long-term commitment to Sagimet Biosciences.
See more insights into SGMT stock on TipRanks’ Stock Analysis page.